Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash from Operations (2019 - 2025)

Historic Cash from Operations for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to -$20.5 million.

  • aTYR PHARMA's Cash from Operations fell 5561.64% to -$20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$62.9 million, marking a year-over-year increase of 615.52%. This contributed to the annual value of -$69.1 million for FY2024, which is 10805.82% down from last year.
  • As of Q3 2025, aTYR PHARMA's Cash from Operations stood at -$20.5 million, which was down 5561.64% from -$13.9 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Cash from Operations ranged from a high of -$590000.0 in Q1 2023 and a low of -$22.4 million during Q1 2024
  • Its 5-year average for Cash from Operations is -$12.0 million, with a median of -$11.5 million in 2021.
  • As far as peak fluctuations go, aTYR PHARMA's Cash from Operations surged by 9416.94% in 2023, and later crashed by 369322.03% in 2024.
  • aTYR PHARMA's Cash from Operations (Quarter) stood at -$8.1 million in 2021, then fell by 28.23% to -$10.4 million in 2022, then fell by 6.68% to -$11.1 million in 2023, then dropped by 18.71% to -$13.1 million in 2024, then crashed by 55.92% to -$20.5 million in 2025.
  • Its last three reported values are -$20.5 million in Q3 2025, -$13.9 million for Q2 2025, and -$15.4 million during Q1 2025.